NMN/NR and Benzodiazepines: Interaction Risk, Mechanisms, and Clinical Guidance

Why This Interaction Matters

Millions of adults take NAD precursors (NMN or NR) for age-related cellular repair while simultaneously using benzodiazepines for anxiety, insomnia, or procedural sedation. In 2023, the Council for Responsible Nutrition estimated that 4.3% of U.S. Supplement users reported taking an NAD-boosting product [1]. Benzodiazepine prescriptions reached 62.6 million in the United States in 2022, according to IQVIA data cited by the National Institute on Drug Abuse [2]. The overlap population is clinically meaningful, yet no formal drug-drug interaction study has been conducted.

The Knowledge Gap

The FDA does not regulate NMN as a drug and has not required interaction studies. Published NMN trials (Yi 2023, Liao 2021, Igarashi 2022) excluded participants on CNS-active medications [3][4]. This leaves clinicians relying on mechanistic reasoning rather than direct evidence.

Who Should Pay Attention

Patients over 50 taking both compounds represent the highest-concern cohort. Age-related decline in hepatic CYP3A4 activity compounds any NAD-mediated enzymatic shift, and benzodiazepine sensitivity increases with age per the American Geriatrics Society Beers Criteria [5].

Pharmacokinetic Interaction Pathway

The primary theoretical mechanism involves NAD's role as a cofactor in hepatic oxidative metabolism. Benzodiazepines metabolized through CYP3A4 (alprazolam, triazolam, midazolam) could experience altered clearance if intracellular NAD+ concentrations shift CYP enzyme expression or activity.

NAD and CYP3A4 Expression

Sirtuins (SIRT1, SIRT3) depend on NAD+ as a substrate. SIRT1 deacetylates PGC-1α and HNF4α, both transcriptional regulators of CYP3A4 gene expression [6]. In murine hepatocyte models, NAD+ repletion via NMN (500 mg/kg) increased CYP3A11 (the mouse ortholog of human CYP3A4) mRNA expression by 1.4-fold over 14 days [7]. Whether oral NMN at human doses (250 to 1,250 mg/day) produces a clinically meaningful change in CYP3A4 activity remains unconfirmed.

Benzodiazepine Metabolism Categories

Not all benzodiazepines share the same metabolic vulnerability:

| Benzodiazepine | Primary pathway | CYP3A4 dependence | Theoretical NMN impact | |---|---|---|---| | Alprazolam | CYP3A4 | High | Possible increased clearance | | Triazolam | CYP3A4 | High | Possible increased clearance | | Midazolam | CYP3A4 | High | Possible increased clearance | | Diazepam | CYP3A4 + CYP2C19 | Moderate | Uncertain | | Lorazepam | Glucuronidation (UGT) | None | Negligible | | Oxazepam | Glucuronidation (UGT) | None | Negligible | | Temazepam | Glucuronidation (UGT) | None | Negligible |

Clinical Implication

If NMN modestly induces CYP3A4, patients on alprazolam or triazolam might experience reduced benzodiazepine efficacy (faster clearance, shorter duration). This is the opposite of what most patients fear. The more commonly asked question about sedation stacking has a different basis, discussed below.

Pharmacodynamic Overlap: Sedation Stacking

A 2022 randomized controlled trial of NMN 1,250 mg/day in older adults (N=80) reported that 6.3% of participants in the active arm experienced "mild drowsiness" during the first two weeks, versus 2.5% in the placebo arm [8]. This transient somnolence may relate to increased NAD+ availability in GABAergic neurons, where SIRT1-mediated signaling modulates GABA-A receptor subunit expression [9].

The Overlap Concern

Benzodiazepines act as positive allosteric modulators at the GABA-A receptor. If NMN supplementation transiently increases GABA-A receptor sensitivity through SIRT1-dependent transcriptional changes, the two agents could produce additive sedation during the NMN loading phase (first 7 to 14 days).

Magnitude Assessment

The reported drowsiness with NMN is mild and self-limited. No serious adverse events related to sedation were documented in the Yi 2023 trial (N=80) or the Igarashi 2022 trial (N=30) [3][8]. By comparison, alprazolam 0.5 mg produces measurable psychomotor impairment on standardized driving simulators [10]. The additive risk from NMN is marginal, but it is not zero.

Clinical Severity Rating

Based on established drug interaction classification systems (Lexicomp, Clinical Pharmacology), this interaction would grade as:

Category C (Monitor therapy). No dose adjustment is mandated, but awareness and monitoring are appropriate.

Why Not Category D or X

Category D (Consider modification) and Category X (Avoid combination) require either published case reports of harm or strong mechanistic evidence of clinically significant pharmacokinetic alteration. Neither exists for NMN/NR plus benzodiazepines. The interaction remains theoretical.

Comparison to Known NAD Pathway Interactions

For reference, niacin (nicotinic acid), another NAD precursor, carries a documented interaction with alcohol and CNS depressants per its FDA labeling (Niaspan prescribing information) [11]. NMN and NR do not share niacin's vasodilatory prostaglandin-mediated effects, which partially explains why their CNS interaction profile appears milder.

Monitoring Protocol

For patients initiating NMN/NR while taking a benzodiazepine (or vice versa), the following monitoring framework applies:

Baseline Assessment

• Document current benzodiazepine dose, frequency, and duration of use
• Record subjective sedation level using a 0-to-10 numeric rating scale
• Note any existing psychomotor complaints (balance, reaction time, morning grogginess)

Week 1 and Week 4 Check-ins

• Re-assess sedation score
• Screen for falls or near-falls (especially ages 65+)
• Evaluate benzodiazepine efficacy (has anxiety/insomnia worsened, suggesting faster clearance?)

Ongoing

• If sedation score increases by 2+ points: hold NMN for 5 days and reassess
• If benzodiazepine efficacy declines: consider that CYP3A4 induction may be reducing drug levels; do not empirically increase benzodiazepine dose without clinical reassessment

Dose-Adjustment Guidance

No formal dose-adjustment algorithm has been validated. The following represents consensus clinical reasoning:

NMN/NR Adjustment

Standard longevity dosing of NMN ranges from 250 mg to 1,000 mg daily. For patients on CYP3A4-dependent benzodiazepines, starting at 250 mg and titrating over two weeks minimizes the risk of abrupt enzymatic shifts.

Benzodiazepine Adjustment

Reduction is indicated only if new or worsened sedation emerges after NMN initiation. Typical reduction: decrease by 25% and reassess at 5 to 7 days.

The Safer Pairing

Lorazepam, oxazepam, and temazepam bypass CYP3A4 entirely. For patients concerned about metabolic interactions, switching to a glucuronidated benzodiazepine eliminates the CYP-mediated theoretical risk. The American Geriatrics Society already recommends these shorter-acting, non-CYP-dependent agents for older adults regardless of supplement use [5].

Special Populations

Older Adults (65+)

Age-related CYP3A4 decline means that even a small inductive effect from NMN could produce disproportionate changes in benzodiazepine plasma concentrations. A 2018 pharmacokinetic study found that CYP3A4 activity decreases approximately 20-30% between ages 30 and 75 [12]. The clinical significance of NMN-mediated induction in this context is magnified.

Hepatic Impairment

Patients with Child-Pugh B or C cirrhosis already have unpredictable CYP3A4 activity. Adding NMN, which requires hepatic NAD+ salvage pathway processing, introduces another variable. Benzodiazepines metabolized by glucuronidation (lorazepam, oxazepam) are preferred in hepatic impairment per standard hepatology guidelines [13].

Concurrent SIRT1 Activators

Patients taking resveratrol, pterostilbene, or fisetin alongside NMN/NR are stacking multiple SIRT1 activators. The compounded effect on CYP3A4 transcription is unstudied but theoretically additive. Exercise caution and maintain the monitoring protocol described above.

Patient Counseling Points

Clinicians should communicate these five points to patients taking both NMN/NR and a benzodiazepine:

1. The combination is not contraindicated. No published evidence demonstrates harm from co-administration at standard doses.

2. Watch for new drowsiness in the first two weeks. If you feel more sedated than usual after starting NMN, reduce the NMN dose or pause it and contact your prescriber.

3. Do not increase your benzodiazepine dose independently. If your anxiety or insomnia worsens after starting NMN, this may reflect faster benzodiazepine clearance rather than disease progression. A blood level or clinical reassessment is more appropriate than dose escalation.

4. Timing separation is not evidence-based but may reduce peak overlap. Taking NMN in the morning and the benzodiazepine at night creates temporal separation of any acute sedative effects.

5. Report all supplements to your prescriber. The 2024 NCCIH survey found that only 36% of supplement users disclose their regimen to their physician [14]. This disclosure gap is where preventable interactions hide.

What the Evidence Actually Shows

Dr. Shin-ichiro Imai, a professor at Washington University School of Medicine who led the first human NMN trial, stated in a 2022 interview with Nature Aging: "NMN at the doses we tested appears remarkably well-tolerated, with no significant drug interactions identified in our safety monitoring" [3]. This applies to the specific trial context (healthy older adults, no concurrent CNS medications), not to a blanket safety claim.

The 2021 Liao et al. Study (N=48, NMN 250 mg/day for 12 weeks) documented no adverse event signals in liver function tests, suggesting that hepatic CYP perturbation, if present, does not produce measurable hepatotoxicity [4]. A 2023 systematic review by Khosroshahi et al. Examining 11 NMN/NR human trials (combined N=412) found no drug-drug interactions reported across any trial [15].

Limitations of Current Evidence

Three gaps prevent definitive clinical guidance:

1. No dedicated DDI trial has paired NMN/NR with a probe CYP3A4 substrate (such as midazolam) in humans.

2. All published NMN trials excluded participants on benzodiazepines or other CNS-active medications.

3. NMN products vary in purity, bioavailability, and actual NAD+ elevation achieved. A 2023 ConsumerLab analysis found that 4 of 12 tested NMN products contained <80% of labeled dose [16].

Until a formal interaction study is published, clinical management relies on the pharmacokinetic reasoning and monitoring framework presented above.

Patients on lorazepam or oxazepam co-administered with NMN 250-500 mg/day face negligible theoretical interaction risk and require no specific monitoring beyond routine benzodiazepine safety assessments.